(Adnkronos) - “Le malattie del sangue, soprattutto quelle oncologiche, sono l'esempio di come la ricerca possa e debba trasformarsi in ricaduta sui pazienti con nuove terapie. Negli ultimi anni abbiamo studiato i meccanismi molecolari che portano alle diverse malattie e identificando le anomalie genetiche, abbiamo identificato degli obiettivi da colpire in maniera molto personalizzata. Sono state così disegnate delle terapie che hanno completamente stravolto l'aspettativa di vita dei pazienti”. Lo dice Paolo Ghia, professore di Oncologia Medica, università Vita-Salute San Raffaele di Milano, a valle della presentazione della campagna di Lilly Italy Hub “#SavingTime. Più tempo grazie alla ricerca sui tumori del sangue”.
Category
🗞
NewsTranscript
00:00The diseases of the blood, especially the oncological diseases of the blood, are just
00:08the example of how research can and should be transformed into a fallback for patients
00:15with new therapies.
00:16This is what has happened in the last 10-15 years, we have studied Italy, it was definitely
00:24in the forefront in this study at a global level, we have studied the molecular mechanisms
00:30that led to the different diseases, leukemias, lymphomas, and identifying the genetic anomalies,
00:36the anomalies of the proteins that are expressed in an anomalous way in each single disease,
00:43we have identified the targets, the objectives to be hit in a very personalized way, very
00:52personalized, so therapies have been designed that have completely overturned the patient's
00:59life expectancy, the response to therapies in general, and therefore have given more
01:06life time to our patients, and above all, much better life time.
01:11What we have learned in these 10-15 years is that we are able to control many of these
01:19diseases, in some cases we are able to cure them completely, so the disease is no longer
01:25represented, they are above all the most aggressive diseases, the most acute, in other cases,
01:31especially in the so-called chronic, painful diseases, we are able to obtain a long-term
01:37control with a life expectancy of patients that is sometimes identical to that of the
01:43individuals not affected by the disease, but we are not able to eradicate the disease completely,
01:48we still need more research to be able to find a way to do a single therapy that eliminates
01:54the disease forever.
01:56We have progressively moved from chemotherapy to biological therapies, very often therapies
02:01that can be taken by mouth and therefore do not even require an infusion or a needle in the
02:08vein, so they are drugs that are much better tolerated because they are more specific on
02:14certain specific mechanisms of the disease, so they give less of those systemic effects,
02:20generalized effects of the collateral effects that we knew in chemotherapy.